|
- Semaglutide - ALZFORUM
Semaglutide is a synthetic, long-acting analog of glucagon-like peptide-1, used to treat diabetes Ozempic TM is a once-per-week injection formulation, while Rybelsus TM is is a daily pill
- NT-0796 | ALZFORUM
In diet-induced obesity in these mice, NT-0796 caused weight loss as potently as did the GLP1 inhibitor semaglutide, and improved markers of cardiovascular risk (Thornton et al , 2024)
- Semaglutide as a possible therapy for healthy aging: Targeting the . . .
Ortiz GU, de Freitas EC Semaglutide as a possible therapy for healthy aging: Targeting the hallmarks of aging Ageing Res Rev 2024 Dec;102:102582 Epub 2024 Nov 14 PubMed
- Neuroprotective Role of the Novel GLP-1R Agonist Semaglutide. | ALZFORUM
Kenzheshova A, Moldasheva A, Aljofan M Neuroprotective Role of the Novel GLP-1R Agonist Semaglutide Curr Med Chem 2025 Apr 23; Epub 2025 Apr 23 PubMed
- Dapagliflozin - ALZFORUM
Type 2 diabetes is a risk factor for developing dementia, and people with Alzheimer’s disease display signs of insulin resistance in the brain These findings have spurred testing of multiple classes of diabetes drug for the treatment or prevention of AD (for example, see nasal insulin, pioglitazone, metformin, liraglutide and semaglutide)
- Semaglutide Attenuates Anxious and Depressive-Like Behaviors and . . .
Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis
- The Discovery and Development of Liraglutide and Semaglutide . . . - ALZFORUM
Knudsen LB, Lau J The Discovery and Development of Liraglutide and Semaglutide Front Endocrinol (Lausanne) 2019;10:155 Epub 2019 Apr 12 PubMed
- Therapeutics - ALZFORUM
AD Target Therapy Types The two tables below organize the therapeutics within this database by therapy type and proposed target type The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U S clinical trials For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total
|
|
|